Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844842 | 0.98 | HRH3 (0.47) | HRH3ALDH1A1SLC6A3SIGMAR1MBTD1 | |
| SCHEMBL5380547 | 0.96 | ALDH1A1 (0.39) | HRH3ALDH1A1SLC6A3SIGMAR1MBTD1 | |
| SCHEMBL27645919 | 0.93 | ALDH1A1 (0.39) | HRH3ALDH1A1SLC6A3SIGMAR1MBTD1 | |
| SCHEMBL159991 | 0.83 | ALDH1A1 (0.53) | HRH3ALDH1A1SIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL1449845 | 0.83 | MC4R (0.55) | ALDH1A1SIGMAR1HRH4CHRNA7KDM4E | |
| SCHEMBL759018 | 0.83 | SIGMAR1 (0.55) | HRH3ALDH1A1SIGMAR1LMNA | |
| SCHEMBL12076753 | 0.82 | SLC6A3 (0.55) | HRH3SLC6A3SIGMAR1MBTD1L3MBTL3 | |
| SCHEMBL4718636 | 0.82 | HRH3 (0.38) | HRH3SIGMAR1GAA | |
| SCHEMBL27708992 | 0.82 | ALDH1A1 (0.51) | HRH3ALDH1A1SIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL9367019 | 0.81 | SIGMAR1 (0.56) | HRH3SLC6A3SIGMAR1MBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | claimed |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-05 | — | — | US | claimed |
| US-11001568-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-11 | — | — | US | claimed |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-21 | — | — | US | claimed |
| EP-3397617-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2018-11-07 | — | — | EP | claimed |
| US-10059687-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-08-28 | — | — | US | claimed |
| WO-2017117154-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-06 | — | — | WO | claimed |
| US-20170183325-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2017-06-29 | — | — | US | claimed |
| WO-2017034377-A1 | PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A ST CO., LTD. (KR) | 2017-03-02 | — | — | WO | claimed |
| US-20170057955-A1 | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-03-02 | — | — | US | claimed |
| EP-1140871-A1 | THROMBIN OR FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2001032628-A1 | CYANO COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-05-10 | — | — | WO | claimed |
| WO-2001005784-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| EP-1058549-A1 | THROMBIN OR FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-12-13 | — | — | EP | claimed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000039102-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038683-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| US-5496844-A | Indole derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-03-05 | — | — | US | claimed |
| EP-0639567-A1 | INDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-02-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001568-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | HRH3 1372/4885ALDH1A1 411/4885SLC6A3 4318/4885 |
| US-11731954-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | HRH3 1372/4885ALDH1A1 411/4885SLC6A3 4318/4885 |
| US-20170183325-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | HRH3 1372/4885ALDH1A1 411/4885SLC6A3 4318/4885 |
| US-20170057955-A1 | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | KDM1B, KDM1A, KDM3B | HRH3 869/4885ALDH1A1 1148/4885SLC6A3 4722/4885 |
| US-10059687-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | HRH3 1372/4885ALDH1A1 411/4885SLC6A3 4318/4885 |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | HRH3 1372/4885ALDH1A1 411/4885SLC6A3 4318/4885 |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | HRH3 1372/4885ALDH1A1 411/4885SLC6A3 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.